DE3277801D1 - Use of 4-aminosalicylic acid as an anti-inflammatory agent - Google Patents

Use of 4-aminosalicylic acid as an anti-inflammatory agent

Info

Publication number
DE3277801D1
DE3277801D1 DE8282810125T DE3277801T DE3277801D1 DE 3277801 D1 DE3277801 D1 DE 3277801D1 DE 8282810125 T DE8282810125 T DE 8282810125T DE 3277801 T DE3277801 T DE 3277801T DE 3277801 D1 DE3277801 D1 DE 3277801D1
Authority
DE
Germany
Prior art keywords
aminosalicylic acid
inflammatory agent
aminosalicylic
acid
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8282810125T
Other languages
English (en)
Inventor
Myron J Lover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stafford Miller Continental NV
Stafford Miller Ltd
Original Assignee
Stafford Miller Continental NV
Stafford Miller Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stafford Miller Continental NV, Stafford Miller Ltd filed Critical Stafford Miller Continental NV
Application granted granted Critical
Publication of DE3277801D1 publication Critical patent/DE3277801D1/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
DE8282810125T 1981-03-18 1982-03-18 Use of 4-aminosalicylic acid as an anti-inflammatory agent Expired DE3277801D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/245,035 US4440763A (en) 1981-03-18 1981-03-18 Use of 4-aminosalicyclic acid as an anti-inflammatory agent

Publications (1)

Publication Number Publication Date
DE3277801D1 true DE3277801D1 (en) 1988-01-21

Family

ID=22925050

Family Applications (2)

Application Number Title Priority Date Filing Date
DE8282810125T Expired DE3277801D1 (en) 1981-03-18 1982-03-18 Use of 4-aminosalicylic acid as an anti-inflammatory agent
DE1999175031 Active DE19975031I2 (de) 1981-03-18 1982-03-18 Verwendung von 4-Aminosalicyls{ure als entz}ndungshemmender Wirkstoff.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1999175031 Active DE19975031I2 (de) 1981-03-18 1982-03-18 Verwendung von 4-Aminosalicyls{ure als entz}ndungshemmender Wirkstoff.

Country Status (7)

Country Link
US (1) US4440763A (de)
EP (1) EP0062000B1 (de)
AT (1) ATE31243T1 (de)
AU (1) AU554443B2 (de)
CA (1) CA1194419A (de)
DE (2) DE3277801D1 (de)
LU (1) LU90386I2 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57500432A (de) * 1980-03-20 1982-03-11
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
DE3151196A1 (de) * 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
USRE33239E (en) * 1983-09-06 1990-06-26 Farmaceutisk Laboratorium Ferring A/S Packaged stable enema solution or suspension containing 5-aminosalicyclic acid
US4657900A (en) * 1983-09-27 1987-04-14 Rowell Laboratories Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method
AU1388388A (en) * 1987-04-01 1988-10-06 Dak-Laboratoriet A/S Benzoic acid derivatives and use thereof
DE3839839A1 (de) * 1988-11-25 1990-05-31 Henning Berlin Gmbh Mittel zur behandlung von chronisch entzuendlichen darmerkrankungen
US5484605A (en) * 1988-11-25 1996-01-16 Henning Berlin Gmbh Chemie-Und Pharmawerk Agent for treating chronically inflammatory intestinal diseases
GB8909559D0 (en) * 1989-04-26 1989-06-14 Smith Kline French Lab Pharmaceutical compositions
US5378470A (en) * 1989-07-25 1995-01-03 Henning Berlin Gmbh Rectally administered pharmaceutical preparation
DE3924570A1 (de) * 1989-07-25 1991-01-31 Henning Berlin Gmbh Pharmazeutische zubereitung zur rektalen verabreichung
SE9000485D0 (sv) * 1990-02-09 1990-02-09 Pharmacia Ab Foamable composition for pharmaceutical use, use thereof and method of treatment
US5120306A (en) * 1990-03-21 1992-06-09 Gosselin Leon F Direct delivery of anti-inflammatories to the proximal small bowel
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US20030198640A1 (en) * 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
US6551632B2 (en) 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
NZ500696A (en) * 1997-04-01 2002-05-31 Borody Thomas J Methods and compositions for treating inflammatory bowel disease comprising mycobacterial agents, including macrolides
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
EP3827747A1 (de) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharmainformatiksystem
US7741359B2 (en) * 2005-05-27 2010-06-22 Antibe Therapeutics Inc. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
WO2006125293A1 (en) * 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
US7498355B2 (en) * 2005-05-27 2009-03-03 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
RU2008152751A (ru) * 2006-06-06 2010-07-20 Антиб Терапьютикс Инк. (Ca) Соли тримебутина и n-десметилтримебутина
CA2663377A1 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US20100136125A1 (en) * 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
US7645801B2 (en) * 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
DK2214679T3 (da) 2007-11-13 2019-05-20 Meritage Pharma Inc Kortikosteroidsammensætninger
EP2398500B1 (de) 2009-02-20 2019-03-13 2-BBB Medicines B.V. Arzneiabgabesystem auf glutathion-basis
SG10201402069PA (en) 2009-05-06 2014-07-30 Lab Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
EP2847158A4 (de) 2012-05-07 2015-12-30 Cellix Bio Private Ltd Zusammensetzungen und verfahren zur behandlung neuromuskulärer erkrankungen und neurodegenerativer erkrankungen
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
AU2013257706A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
JP6202287B2 (ja) 2012-05-23 2017-09-27 セリックスビオ プライヴェート リミテッド 炎症性腸疾患の治療のための組成物及び方法
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
CN104364231A (zh) 2012-09-08 2015-02-18 塞利克斯比奥私人有限公司 用于治疗炎症和脂质异常的组合物和方法
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
SG11201703369WA (en) 2014-10-27 2017-05-30 Cellix Bio Private Ltd Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA2973178C (en) 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2639294A (en) * 1947-12-11 1953-05-19 Ferrosan Ab Method of producing nu-substituted derivatives of 4-amino-2-hydroxybenzoic acid
US2580195A (en) * 1948-01-31 1951-12-25 Ferrosan Ab Method of purifying 4-aminosalicylic acid
US2766278A (en) * 1951-08-10 1956-10-09 Rheinpreussen Ag 4-monoalkylaminosalicylic acids and 4-monoalkyloxyalkylaminosalicylic acids
US2711423A (en) * 1953-07-06 1955-06-21 American Cyanamid Co Neutral calcium 4-aminosalicylate hemihydrate and preparation of the same
US2874177A (en) * 1955-06-25 1959-02-17 Gohei Tanabe & Co Ltd Novel complex salt of 4-aminosalicylic acid and processes for producing the same
GB2021409B (en) * 1977-05-25 1982-09-22 Fisons Ltd Pharmaceutical composition

Also Published As

Publication number Publication date
ATE31243T1 (de) 1987-12-15
DE19975031I2 (de) 2004-09-23
EP0062000A3 (en) 1983-07-27
AU554443B2 (en) 1986-08-21
LU90386I2 (fr) 1999-06-24
US4440763A (en) 1984-04-03
EP0062000B1 (de) 1987-12-09
CA1194419A (en) 1985-10-01
AU8165982A (en) 1982-09-23
EP0062000A2 (de) 1982-10-06

Similar Documents

Publication Publication Date Title
DE3277801D1 (en) Use of 4-aminosalicylic acid as an anti-inflammatory agent
DE3585981D1 (de) Behandlung gewebedegenerativer entzuendungskrankheiten.
NL191332C (nl) Farmaceutisch preparaat met de ethylester van (all-Z)-5,8,11,14,17-eicosapentaeenzuur.
IT8223892A0 (it) Composizione di antralina migliorata e suo uso nel trattamento di malattie della pelle.
ES478967A1 (es) Un procedimiento para preparar compuestos de acido 3-cefem-4-carboxilico disustituido en las posiciones 3 y 7.
DE2963572D1 (en) Mercapto-imidazole derivatives, their preparation, mercapto-imidazole derivatives for the treatment of inflammatory diseases and their pharmaceutical compositions
NL187786C (nl) Injecteerbare oplossing van tetracycline in water; therapeutisch voorwerp.
ZA855224B (en) Pyrrol-1-ylphenyldihydropyridazinones,their preparation and their use
NL7804192A (nl) Cyclohexaancarbonzuur en de derivaten hiervan, evenals de toepassing van deze stoffen als therapeutisch mid- del.
IT8223309A0 (it) Composizione farmaceutica per il trattamento di malattie cardiovascolari.
MX9704150A (es) Uso de l-carnitinas de alcanoilo para el tratamiento de enfermedades del intestino cronicas, inflamatorias.
IL65936A (en) Chloroacetic acid cyclohexylamides,their preparation and their use as herbicides
AU531314B2 (en) Therapeutic agent containing human urinary acid protease
IT7819623A0 (it) Composizione adatta alla purificazione del sangue e suoi impieghi.
ZA792554B (en) Pharmalceutical compositions for use in the treatment of diabetic nephropathy
JPS51119904A (en) Brush system of dc motor
JPS5238506A (en) Detergent composition
JPS57181041A (en) Novel nitrobenzoic acid derivative, manufacture and use
IL57838A0 (en) N-cyclohexyl-n-methoxyacetamide,its preparation and its use in the preparation of o-methyl-n-cyclohexyl-2,5-dimethylfuran-3-hydroxamic acid
JPS5213495A (en) Calcinfd plaster for extrusion molding
JPS5245159A (en) Livestock house discharge treatment system
JPS5319790A (en) Electrochemical display body
HUT62447A (en) Composition disinfecting and indicating body paris
CA603219A (en) 5:5'-dinitro-2:2'-dichloro benzil
JPS52156823A (en) 2-phenoxymuconic acid and its preparation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
V448 Application of spc

Free format text: PRODUCT NAME: 4-AMINO-2-HYDROXYBENZOESAEURE (4-AMINO-SALICYLSAEURE), NATRIUMSALZ 2 H2O; REGISTRATION NO/DATE: 43742.00.00, 19981008

Spc suppl protection certif: 199 75 031

Filing date: 19990330

V457 Spc granted

Free format text: PRODUCT NAME: 4-AMINO-2-HYDROXYBENZOESAEURE (4-AMINO-SALICYLSAEURE), NATRIUMSALZ 2 H2O; REGISTRATION NO/DATE: 43742.00.00, 19981008

Spc suppl protection certif: 199 75 031

Filing date: 19990330

V464 Spc expired

Free format text: PRODUCT NAME: 4-AMINO-2-HYDROXYBENZOESAEURE (4-AMINO-SALICYLSAEURE), NATRIUMSALZ 2 H2O; REGISTRATION NO/DATE: 43742.00.00, 19981008

Spc suppl protection certif: 199 75 031

Filing date: 19990330